Abstract
Recent studies have outlined the emerging role of 68Ga-PSMA-11 PET/CT in the diagnostic algorithm of clear cell renal cell carcinoma (ccRCC). We report a unique intra-patient comparison of bilateral primary ccRCC imaged with 68Ga-PSMA-11 PET/CT. Although both tumors resulted 68Ga-PSMA-11 avid, we found a remarkable discrepancy in uptake intensity between the high grade and the low grade ccRCC. This case confirms previous evidence reporting that SUVmax on 68Ga-PSMA-11 PET/CT could be used to discriminate aggressive high grade from more indolent low grade ccRCC, due to their different endothelial expression of PSMA.
This is a preview of subscription content, log in via an institution to check access.
References
Urso L, Castello A, Rocca GC, Lancia F, Panareo S, Cittanti C, et al. Role of PSMA-ligands imaging in renal cell carcinoma management: current status and future perspectives. J Cancer Res Clin Oncol. 2022;148:1299–311.
Rowe SP, Gorin MA, Hammers HJ, Som Javadi M, Hawasli H, Szabo Z, et al. Imaging of metastatic clear cell renal cell carcinoma with PSMA-targeted 18F-DCFPyL PET/CT. Ann Nucl Med. 2015;29:877–82.
Mittlmeier LM, Unterrainer M, Rodler S. Todica & A, Albert NL, Burgard C, et al. 18F-PSMA-1007 PET/CT for response assessment in patients with metastatic renal cell carcinoma undergoing tyrosine kinase or checkpoint inhibitor therapy: preliminary results. Eur J Nucl Med Mol Imaging. 2021;48:2031–7.
Urso L, Rocca GC, Uccelli L, Ippolito C, Bartolomei M. 18 F-choline versus 68 Ga-PSMA-11 PET/CT imaging comparison in incidental clear cell renal cell carcinoma. Clin Nucl Med. 2023;48:e178–80.
Gaudreault M, Chang D, Hardcastle N, McIntosh L, Jackson P, Kron T, et al. Feasibility of biology-guided radiotherapy for metastatic renal cell carcinoma driven by PSMA PET imaging. Clin Transl Radiat Oncol. 2023;40:100608.
Spatz S, Tolkach Y, Jung K, Stephan C, Busch J, Ralla B, et al. Comprehensive evaluation of prostate specific membrane antigen expression in the vasculature of renal tumors: implications for imaging studies and prognostic role. J Urol. 2018;199:370–7.
Gao J, Xu Q, Fu Y, He K, Zhang C, Zhang Q, et al. Comprehensive evaluation of 68Ga-PSMA-11 PET/CT parameters for discriminating pathological characteristics in primary clear-cell renal cell carcinoma. Eur J Nucl Med Mol Imaging. 2021;48:561–9.
Availability of Data and Material
Data sharing not applicable to this article as no datasets were generated or analysed during the current study.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
Luca Urso, Giovanni Christian Rocca, Grazia Maria Conti, Alessandro Colella, Alberto Nieri, Corrado Cittanti, Carmelo Ippolito, and Mirco Bartolomei declare no competing interests.
Ethical Approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. For this type of study, formal consent is not required.
Consent for Publication
Informed consent was obtained from the participant included in the study.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Urso, L., Rocca, G.C., Conti, G.M. et al. 68Ga-PSMA-11 PET/CT in Bilateral Clear Cell Renal Cell Carcinoma: an Intra-patient Comparison Between High and Low Grade Tumors. Nucl Med Mol Imaging 57, 298–300 (2023). https://doi.org/10.1007/s13139-023-00805-6
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13139-023-00805-6